Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
Globe Newswire•04/11/2026•09:00 ET
0
Key Highlights
- ➤Cellectar (CLRB) reports updated 12-month CLOVER WaM data showing durable responses
- ➤Duration of response was significantly longer after two prior therapy lines
- ➤Phase 3 WM trial site activation advances; first dosing remains targeted for 1Q 2027
- ➤FDA accelerated approval filing remains targeted for 1H27
Expert Statements
Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences
“The new data being presented at ASH further strengthen the clinical profile of iopofosine I 131, underscoring its potential to deliver durable responses and address a significant unmet need in relapsed or refractory Waldenström macroglobulinemia.”
Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences
“These updated CLOVER WaM results demonstrate durable responses in heavily pretreated patients, while new analyses suggest the potential for even greater durability of benefit when iopofosine I 131 is used in earlier lines of therapy.”
Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences
“These findings reinforce our confidence in its clinical potential as we advance our registrational strategy.”
Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences
“In parallel, we are targeting the first half of 2027 for an FDA submission seeking accelerated approval.”
Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences
“These planned milestones define a clear path forward as we work to bring iopofosine I 131 to patients with limited treatment options.”
Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm
Company to present Phase 3 trial-in-progress design as site activation advances, first patient dosing remains on track for 1Q 2027 and FDA filing for accelerated approval remains targeted for 1H27
Get started
Create a free account to read the full story.